Distribution of the unconfined compressive strength of specimens at different positions under different filling speeds: (a) Working condition M1; (b) Working condition M2; (c) Work... by Xiaoyan Ding (291429)

Subjects:

General linear mixed model coefficients and significance for species-specific ungulate intensity of use as a function of cattle grazing period. by Kathryn Knodel (20036529)

Forest plot for the significant MR association between four mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Subjects:

Altered expression of genes related to Ca²⁺ cycling or myocardial contraction. by Hongyu Li (1332669)

Subjects:

miRNA 221 alleviated calcium overload in myocardium and inhibited the expression of apoptosis-related genes in MIRI mice. by Hongyu Li (1332669)

Subjects:

The heart rate was similar among the groups. by Hongyu Li (1332669)

Subjects:

S1 File - by Hongyu Li (1332669)

Subjects:

PLB is a target gene of miRNA 221. by Hongyu Li (1332669)

Subjects:

miRNA 221 alleviated myocardial injury and inhibited apoptosis and necrosis of cardiac cells in MIRI mice. by Hongyu Li (1332669)

Subjects:

Primer sequences for RT-qPCR. by Hongyu Li (1332669)

Subjects:

miRNA 221 improved left ventricular contractile function in MIRI mice. by Hongyu Li (1332669)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: